|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ALOX5AP |
Gene summary for ALOX5AP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ALOX5AP | Gene ID | 241 |
| Gene name | arachidonate 5-lipoxygenase activating protein | |
| Gene Alias | FLAP | |
| Cytomap | 13q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0002526 | UniProtAcc | A0A087WW23 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 241 | ALOX5AP | CA_HPV_3 | Human | Cervix | CC | 6.29e-06 | -4.88e-01 | 0.0414 |
| 241 | ALOX5AP | N_HPV_2 | Human | Cervix | N_HPV | 1.93e-05 | -2.75e-01 | -0.0131 |
| 241 | ALOX5AP | CCI_1 | Human | Cervix | CC | 1.53e-11 | -9.43e-01 | 0.528 |
| 241 | ALOX5AP | CCI_2 | Human | Cervix | CC | 1.96e-08 | -9.21e-01 | 0.5249 |
| 241 | ALOX5AP | CCI_3 | Human | Cervix | CC | 1.91e-12 | -9.12e-01 | 0.516 |
| 241 | ALOX5AP | CCII_1 | Human | Cervix | CC | 4.49e-21 | -9.43e-01 | 0.3249 |
| 241 | ALOX5AP | Tumor | Human | Cervix | CC | 1.31e-40 | -9.40e-01 | 0.1241 |
| 241 | ALOX5AP | sample1 | Human | Cervix | CC | 1.08e-17 | -9.43e-01 | 0.0959 |
| 241 | ALOX5AP | sample3 | Human | Cervix | CC | 6.04e-40 | -9.32e-01 | 0.1387 |
| 241 | ALOX5AP | H2 | Human | Cervix | HSIL_HPV | 6.25e-37 | -9.24e-01 | 0.0632 |
| 241 | ALOX5AP | L1 | Human | Cervix | CC | 5.30e-13 | -7.74e-01 | 0.0802 |
| 241 | ALOX5AP | T1 | Human | Cervix | CC | 3.07e-33 | -9.28e-01 | 0.0918 |
| 241 | ALOX5AP | T2 | Human | Cervix | CC | 2.46e-07 | -8.97e-01 | 0.0709 |
| 241 | ALOX5AP | T3 | Human | Cervix | CC | 9.40e-40 | -9.38e-01 | 0.1389 |
| 241 | ALOX5AP | LZE7T | Human | Esophagus | ESCC | 4.48e-02 | 6.82e-01 | 0.0667 |
| 241 | ALOX5AP | LZE6T | Human | Esophagus | ESCC | 6.49e-11 | 1.06e+00 | 0.0845 |
| 241 | ALOX5AP | C21 | Human | Oral cavity | OSCC | 5.93e-06 | 3.68e-01 | 0.2678 |
| 241 | ALOX5AP | C38 | Human | Oral cavity | OSCC | 3.09e-11 | 1.75e+00 | 0.172 |
| 241 | ALOX5AP | C46 | Human | Oral cavity | OSCC | 5.08e-09 | 2.33e-01 | 0.1673 |
| 241 | ALOX5AP | C51 | Human | Oral cavity | OSCC | 2.81e-06 | 6.11e-01 | 0.2674 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
| GO:00988699 | Cervix | CC | cellular oxidant detoxification | 30/2311 | 101/18723 | 2.72e-06 | 7.93e-05 | 30 |
| GO:00313494 | Cervix | CC | positive regulation of defense response | 60/2311 | 278/18723 | 9.38e-06 | 2.11e-04 | 60 |
| GO:00507273 | Cervix | CC | regulation of inflammatory response | 75/2311 | 386/18723 | 3.95e-05 | 6.18e-04 | 75 |
| GO:19907489 | Cervix | CC | cellular detoxification | 30/2311 | 116/18723 | 5.34e-05 | 7.94e-04 | 30 |
| GO:00972379 | Cervix | CC | cellular response to toxic substance | 31/2311 | 124/18723 | 8.09e-05 | 1.10e-03 | 31 |
| GO:00507294 | Cervix | CC | positive regulation of inflammatory response | 34/2311 | 142/18723 | 9.51e-05 | 1.25e-03 | 34 |
| GO:00096369 | Cervix | CC | response to toxic substance | 52/2311 | 262/18723 | 3.34e-04 | 3.52e-03 | 52 |
| GO:00987549 | Cervix | CC | detoxification | 33/2311 | 152/18723 | 7.97e-04 | 7.00e-03 | 33 |
| GO:001003810 | Cervix | CC | response to metal ion | 67/2311 | 373/18723 | 9.67e-04 | 8.10e-03 | 67 |
| GO:00515926 | Cervix | CC | response to calcium ion | 31/2311 | 149/18723 | 2.31e-03 | 1.65e-02 | 31 |
| GO:00464564 | Cervix | CC | icosanoid biosynthetic process | 15/2311 | 56/18723 | 2.60e-03 | 1.80e-02 | 15 |
| GO:0070206 | Cervix | CC | protein trimerization | 7/2311 | 17/18723 | 2.72e-03 | 1.85e-02 | 7 |
| GO:005072711 | Cervix | HSIL_HPV | regulation of inflammatory response | 41/737 | 386/18723 | 8.30e-09 | 1.03e-06 | 41 |
| GO:003210312 | Cervix | HSIL_HPV | positive regulation of response to external stimulus | 41/737 | 427/18723 | 1.40e-07 | 9.01e-06 | 41 |
| GO:001003815 | Cervix | HSIL_HPV | response to metal ion | 36/737 | 373/18723 | 7.19e-07 | 3.65e-05 | 36 |
| GO:005072911 | Cervix | HSIL_HPV | positive regulation of inflammatory response | 20/737 | 142/18723 | 7.56e-07 | 3.79e-05 | 20 |
| GO:003134911 | Cervix | HSIL_HPV | positive regulation of defense response | 28/737 | 278/18723 | 5.45e-06 | 2.07e-04 | 28 |
| GO:004645611 | Cervix | HSIL_HPV | icosanoid biosynthetic process | 10/737 | 56/18723 | 5.80e-05 | 1.40e-03 | 10 |
| GO:000963614 | Cervix | HSIL_HPV | response to toxic substance | 24/737 | 262/18723 | 1.14e-04 | 2.36e-03 | 24 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04664 | Cervix | CC | Fc epsilon RI signaling pathway | 22/1267 | 68/8465 | 2.35e-04 | 1.31e-03 | 7.77e-04 | 22 |
| hsa046641 | Cervix | CC | Fc epsilon RI signaling pathway | 22/1267 | 68/8465 | 2.35e-04 | 1.31e-03 | 7.77e-04 | 22 |
| hsa046642 | Oral cavity | EOLP | Fc epsilon RI signaling pathway | 23/1218 | 68/8465 | 4.23e-05 | 2.01e-04 | 1.19e-04 | 23 |
| hsa0466411 | Oral cavity | EOLP | Fc epsilon RI signaling pathway | 23/1218 | 68/8465 | 4.23e-05 | 2.01e-04 | 1.19e-04 | 23 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ALOX5AP | SNV | Missense_Mutation | novel | c.640N>G | p.Leu214Val | p.L214V | protein_coding | deleterious_low_confidence(0) | benign(0.138) | TCGA-A7-A5ZW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR | |
| ALOX5AP | insertion | Frame_Shift_Ins | novel | c.189_205dupAGGCAATGTTGTCCTGT | p.Leu69Ter | p.L69* | protein_coding | TCGA-B6-A0I1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |||
| ALOX5AP | SNV | Missense_Mutation | rs776630925 | c.246C>A | p.Phe82Leu | p.F82L | protein_coding | deleterious(0.02) | benign(0.382) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| ALOX5AP | SNV | Missense_Mutation | rs770152662 | c.214N>A | p.Val72Ile | p.V72I | protein_coding | tolerated(0.06) | benign(0.007) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ALOX5AP | SNV | Missense_Mutation | rs768839702 | c.229G>A | p.Val77Met | p.V77M | protein_coding | deleterious(0) | probably_damaging(0.911) | TCGA-AJ-A8CT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ALOX5AP | SNV | Missense_Mutation | c.521N>A | p.Arg174His | p.R174H | protein_coding | deleterious(0.05) | probably_damaging(0.996) | TCGA-AX-A05S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unspecific | Carboplatin & Paclitaxel | PD | ||
| ALOX5AP | SNV | Missense_Mutation | novel | c.226A>T | p.Ser76Cys | p.S76C | protein_coding | deleterious(0.01) | probably_damaging(0.922) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| ALOX5AP | SNV | Missense_Mutation | novel | c.164N>G | p.Glu55Gly | p.E55G | protein_coding | deleterious_low_confidence(0.04) | benign(0.003) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | |
| ALOX5AP | SNV | Missense_Mutation | novel | c.459G>T | p.Lys153Asn | p.K153N | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ALOX5AP | SNV | Missense_Mutation | c.251N>T | p.Ala84Val | p.A84V | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 241 | ALOX5AP | DRUGGABLE GENOME | DG031 | |||
| 241 | ALOX5AP | DRUGGABLE GENOME | AM-103 | |||
| 241 | ALOX5AP | DRUGGABLE GENOME | inhibitor | CHEMBL1922660 | FIBOFLAPON | |
| 241 | ALOX5AP | DRUGGABLE GENOME | AM-803 | FIBOFLAPON | ||
| 241 | ALOX5AP | DRUGGABLE GENOME | inhibitor | CHEMBL1922673 | FIBOFLAPON SODIUM | |
| 241 | ALOX5AP | DRUGGABLE GENOME | IL-3 | 11246129 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |